Company: SRPT
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058003
Chunk: 71

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 71
---
.S. sales

Clinical Programs

SRP-5051 :

Discontinuation. Despite announcing positive data from Part B of Momentum (a Phase 2 study of SRP-5051) earlier in 2024, we made the decision to discontinue the SRP-5051 development program in the third quarter of 2024. This decision was based in part on information available to date, including the risk-benefit of the program, feedback from the FDA, and the evolving therapeutic landscape for Duchenne.

SRP-9003 (LGMD2E) :

Fast Track Designation . In the second quarter of 2024, the FDA granted Fast Track designation to SRP-9003 (bidridistrogene xeboparvovec). SRP-9003 is an investigational gene therapy for the treatment of limb-girdle muscular dystrophy Type 2E/R4 (LGMD2E/R4), or beta-sarcoglycanopathy. The Fast Track designation is a process designed to facilitate the development and expedited review of drugs that treat serious conditions and fill unmet medical needs.

EMERGENE. In December 2024, we completed enrollment and dosing in EMERGENE (Study SRP-9003-301), a Phase 3 clinical trial of SRP-9003.

Other Notable Events

Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals, Inc. :

We obtained an exclusive worldwide license to four clinical-stage and three preclinical-stage programs in muscle, central nervous system, and rare pulmonary disorders, including potential best-in-class siRNA-based treatments for myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD).

Additionally, the parties entered into a discovery partnership pursuant to which we will nominate, and Arrowhead will deliver, IND-ready constructs for six targets across skeletal muscle, cardiac, and CNS.

Named Executive Officer Compensation. The Company’s accomplishments in 2024 were directly tied to the performance of the Company’s named executive officers, and thus were an important factor in determining the named executive officers’ compensation for 2024. In light of these significant accomplishments, certain of which are summarized above and detailed further below, our named executive officers received the following compensation for 2024:

Annual cash bonus awards in an amount equal to 130% of their target bonuses, based on the achievement of pre-established corporate goals approved by the compensation committee and Board;

<div align='center'>45